FPT-CORPORATION
1.3.2024 08:37:38 CET | Business Wire | Press release
FPT Corporation (FPT) has acquired the IT services company Next Advanced Communications NAC Co., Ltd. (NAC), making it FPT’s first merger & acquisition (M&A) deal in Japan. With NAC as FPT’s wholly-owned subsidiary, the company aims to double its customer base and service offerings, deepening its foothold in the Japanese market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229752610/en/
The strategic investment signing ceremony between NAC and FPT took place in Tokyo, Japan (Photo: Business Wire)
The strategic move aligns with FPT’s global expansion strategy and enables the Vietnamese firm to capitalize on NAC’s talent pool of nearly 300 experienced engineers and strong expertise centred on technology and business consulting, architecture design, system planning, design, development, and operation. With these additional resources, FPT aims to achieve one billion USD in revenue from the Japanese market by 2027 and have more than half of its employees in Japan as multinational employees.
With current challenges for digital transformation in Japan, including an ageing population, shortage of ICT human resources and complexity of existing systems, the acquisition of NAC reflects FPT’s commitment to accompanying Japanese businesses in digital transformation and green transformation. This also enables FPT to foster sustainable growth and competitiveness and expand its services to new industries and a wider range of customers.
"Like NAC, FPT strives to leverage technology to address a variety of customer issues, with the goal of creating a sustainable society for everyone. We aim to enhance the Japanese engineer talent pool and cooperate with local companies to help our clients maintain business continuity despite geopolitical challenges. Additionally, FPT prioritizes and fosters a multicultural work environment. I believe NAC and FPT employees will find greater success and happiness in our collaboration," said Do Van Khac, FPT Software Senior Executive Vice President and FPT Japan CEO.
Naoto Yamazaki, NAC Chairman, said: “Since we started NAC 13 years ago, we have achieved success as an independent company. Today, as we join the FPT family, I believe not only can we maintain our growth but also form a stronger synergy for the future. NAC and FPT will strive to accelerate our business more than ever and become a company that can contribute to society.”
Since 2014, FPT has completed multiple M&A deals in the US and Europe. In Japan, the firm recently formed a joint venture with Konica Minolta and made a strategic investment in LTS Inc. The acquisition of NAC, as FPT’s first M&A deal in Japan, highlights its focused, long-term commitment to this key market. This also generates momentum for the corporation’s future M&A activities.
FPT has nearly two decades of presence in the Japanese market with the operation of FPT Japan, one of the country’s largest foreign-invested tech firms in terms of human resources. With a workforce of 2,900 onsite employees, nearly 15,000 employees working from overseas, 16 local offices and innovation hubs, FPT Japan has provided services and solutions to over 450 clients worldwide. The company is also recognized for excellent employee benefits and workplace happiness, earning accolades such as Best Workplaces in Asia, Best Places To Work in Japan, and Best Places To Work for Women in Japan.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.
About NAC Co., Ltd.
NAC Co., Ltd. was established on March 31, 2011. The company's main businesses are marketing, consulting support, system planning, and system design, development, operation, and maintenance. By providing these services, NAC aims to realize a sustainable future as a member of the FPT Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229752610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom